DURHAM, NC & SEATTLE, WA, USA I November 14, 2024 ILeading epigenome editing company Tune Therapeutics announced today that it has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) to initi...
Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common, chronic and age-related diseases that are straining healthcare systems and limiting human healthspa
Based in Durham, Nc. and Seattle, Wa., Tune was founded and built around a veteran leadership team with expertise in gene and cell therapy, genome editing, and epigenetics
374, Addgene, Cambridge, MA) by the Center for Targeted Therapeutics Core Facility at the University of South Carolina (Columbia, SC) followed by lentiviral particle generation. Infected cells were sorted by dTomato expression at the flow cytometry...